ArticleAdvanced biomedical research2025
The Association of
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is ranked as the most widespread malignancy, among men with the second level of mortality in the United States after lung cancer. Despite the low frequency of prostate cancer incidence in Iran, it has been informed as the fourth most predominant cancer among men with 6% of all deaths from cancer. Recent studies suggest that several hot spot points are indirectly associated with the incidence of prostate neoplasm. Our study aimed to test whether two different ITGBL1 and LPPR4/PRG1 gene expression levels are linked with prostate cancer incidence. Materials and Methods: 40 prostate tissue biopsies representing confirmed cancer and 41 normal tissues were selected. RNA extraction, cDNA synthesis, and TaqMan Real-time PCR were done according to the standard guidelines. Results: Among all 81 biopsy samples that were analyzed, expression levels of ITGBL1 have been significantly elevated in patients with prostate cancer. Also, the results of the present study showed that there was no significant correlation between LPPR4/PRG1 expression levels (2.79 ± 3.83) with prostate cancer incidence, while there has been no association between LPPR4/PRG1 expression levels (1.85 ± 1.55) in a patient with prostate cancer history out of control. Conclusion: According to the role of ITGBL1 in several tumor phenotypes, we cannot ignore the importance of ITGBL1 genes as one of the critical regulatory proteins in prostate cancer development or progression. Therefore, more studies are required to explore the associations of prostate cancer with these regulatory proteins in more Iranian populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.